HRP20210283T1 - Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu - Google Patents
Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu Download PDFInfo
- Publication number
- HRP20210283T1 HRP20210283T1 HRP20210283TT HRP20210283T HRP20210283T1 HR P20210283 T1 HRP20210283 T1 HR P20210283T1 HR P20210283T T HRP20210283T T HR P20210283TT HR P20210283 T HRP20210283 T HR P20210283T HR P20210283 T1 HRP20210283 T1 HR P20210283T1
- Authority
- HR
- Croatia
- Prior art keywords
- percent
- weight
- preparation
- cutaneous
- skin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- 229940100198 alkylating agent Drugs 0.000 title 1
- 239000002168 alkylating agent Substances 0.000 title 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 206010037127 Pseudolymphoma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 210000003567 ascitic fluid Anatomy 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000007282 lymphomatoid papulosis Diseases 0.000 claims 1
- 208000025036 lymphosarcoma Diseases 0.000 claims 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 claims 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (5)
1. Pripravak koji se sastoji od:
0.02 težinskih postotaka mekloretamin hidroklorida;
2.00 težinskih postotaka hidroksipropil celuloze;
0.01 težinskih postotaka dinatrijevog edetat dihidrata;
0.05 težinskih postotaka racemičnog mentola;
0.01 težinskih postotaka butiliranog hidroksitoulena;
49.91 težinskih postotaka 2-(2-etoksi-etoksi)etanola;
15.27 težinskih postotaka izopropilnog alkohola;
17.57 težinskih postotaka propilen glikola;
11.33 težinskih postotaka glicerina;
3.65 težinskih postotaka racemične mliječne kiseline; i
0.18 težinskih postotaka natrijevog klorida,
za upotrebu kao lijek.
2. Pripravak prema patentnom zahtjevu 1 za upotrebu u lokalnom liječenju poremećaja kože.
3. Pripravak za upotrebu prema patentnom zahtjevu 2, naznačen time što je poremećaj kože izabran iz grupe koja se sastoji od psorijaze, ekcema, aktinične keratoze, lupusa, sarkoidoze, alopecije, kožnog T-staničnog limfoma (tj. mycosis fungoides), limforetikularne neoplazije, pleuralnog i peritonealnog izljeva, kožnog B-staničnog limfoma, pseudolimfoma kože, karcinoma skvamoznih stanica, karcinoma bazalnih stanica, bronhogenog karcinoma, malignog melanoma, limfosarkoma, kronične limfocitne leukemije, policitemije vere, limfomatoidne papuloze, Mucha-Habbermanove bolesti, vitiliga, i njihovih kombinacija.
4. Pripravak za upotrebu prema patentnom zahtjevu 3, naznačen time što je poremećaj kože vitiligo.
5. Pripravak za upotrebu prema patentnom zahtjevu 3, naznačen time što je poremećaj kože kožni T-stanični limfom (tj. mycosis fungoides).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3984008P | 2008-03-27 | 2008-03-27 | |
| EP18214529.2A EP3494960B1 (en) | 2008-03-27 | 2009-03-11 | Stabilized compositions of alkylating agents and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210283T1 true HRP20210283T1 (hr) | 2021-04-02 |
Family
ID=41114573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190551TT HRP20190551T1 (hr) | 2008-03-27 | 2019-03-21 | Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu |
| HRP20210283TT HRP20210283T1 (hr) | 2008-03-27 | 2021-02-18 | Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190551TT HRP20190551T1 (hr) | 2008-03-27 | 2019-03-21 | Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8501817B2 (hr) |
| EP (2) | EP3494960B1 (hr) |
| CN (2) | CN107149591A (hr) |
| CY (2) | CY1121777T1 (hr) |
| DK (1) | DK3494960T3 (hr) |
| ES (2) | ES2727523T3 (hr) |
| HR (2) | HRP20190551T1 (hr) |
| HU (2) | HUE043767T2 (hr) |
| LT (2) | LT3494960T (hr) |
| PL (2) | PL2273876T3 (hr) |
| PT (2) | PT2273876T (hr) |
| SI (2) | SI2273876T1 (hr) |
| TR (1) | TR201907794T4 (hr) |
| WO (1) | WO2009120493A2 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110039943A1 (en) * | 2005-03-14 | 2011-02-17 | Robert Alonso | Methods for treating skin disorders with topical nitrogen mustard compositions |
| US7872050B2 (en) * | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| US8501818B2 (en) * | 2005-03-14 | 2013-08-06 | Ceptaris Therapeutics, Inc. | Stabilized compositions of alkylating agents and methods of using same |
| LT3494960T (lt) * | 2008-03-27 | 2021-02-25 | Helsinn Healthcare Sa | Stabilizuotos alkilinimo agentų kompozicijos ir jų naudojimo būdai |
| US20180125797A1 (en) * | 2016-11-07 | 2018-05-10 | Actelion Pharmaceuticals Ltd | Methods for treating skin disorders with a topical composition of bis-(2-chloroethyl)methylamine |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4083692A (en) | 1970-06-04 | 1978-04-11 | The United States Of America As Represented By The Secretary Of The Army | Detection and estimation of microquantities of alkylating agents |
| US3767792A (en) | 1971-07-02 | 1973-10-23 | Stanley Drug Products Inc | Method for controlling the toxicity of drug products |
| US3904766A (en) | 1973-06-19 | 1975-09-09 | Scott Eugene J Van | Treatment of psoriasis |
| US4206222A (en) | 1977-06-23 | 1980-06-03 | Societe Civile Particuliere De Brevets Suffren | Method for preparing a substance having properties against collagen diseases and products obtained |
| AU605132B2 (en) | 1986-01-03 | 1991-01-10 | Consolidated Pharmaceuticals Limited | Melphalan derivatives |
| US4863910A (en) | 1986-05-20 | 1989-09-05 | Takeo Takayanagi | Complexes of AZO compounds and/or their salts and an antitumor agent and a method for reducing the growth of tumors |
| US4725438A (en) | 1986-05-29 | 1988-02-16 | Leazer Billie S | Aloe vera ointment |
| IE60588B1 (en) | 1986-07-30 | 1994-07-27 | Sumitomo Pharma | Carbapenem compound in crystalline form, and its production and use |
| US5326790A (en) | 1986-11-19 | 1994-07-05 | Dermatologic Research Corporation | Administration of skin medications by use of dicarboxylic acids and derivatives |
| US4853388A (en) | 1987-05-15 | 1989-08-01 | Pearlman Dale L | Method for treating psoriasis with cytotoxic agents |
| US5051363A (en) | 1987-06-26 | 1991-09-24 | University Of Pennsylvania | Method for modifying the toxicity of DNA reactive cross-linking agents to cells |
| US5229422A (en) | 1987-09-07 | 1993-07-20 | Teijin Limited | Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion |
| GB8727157D0 (en) | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| US4888354A (en) | 1987-12-21 | 1989-12-19 | Theratech, Inc. | Skin penetration enhancement using free base and acid addition salt combinations of active agents |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US4949641A (en) | 1990-03-05 | 1990-08-21 | The United States Of America As Represented By The Secretary Of The Army | Method of safely detoxifying mustard gases |
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5820872A (en) | 1992-11-18 | 1998-10-13 | Yale University | Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor |
| EP0716589A4 (en) | 1993-07-23 | 1997-06-11 | Morris Herstein | COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT |
| FR2728166A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
| GB9501052D0 (en) * | 1995-01-19 | 1995-03-08 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| US6551611B2 (en) | 1995-09-28 | 2003-04-22 | Schering Aktiengesellschaft | Hormone replacement therapy method |
| US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
| US6124108A (en) | 1996-05-15 | 2000-09-26 | The United States Of America As Represented By The Secretary Of The Army | Protein biomarker for mustard chemical injury |
| US5948437A (en) | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| DK0923941T3 (da) | 1996-06-27 | 2006-09-18 | Chugai Pharmaceutical Co Ltd | Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler |
| IL127956A0 (en) | 1996-07-11 | 1999-11-30 | Farmarc Nederland Bv | Inclusion complex containing indole selective serotonin agonist |
| US6753155B1 (en) | 1997-05-13 | 2004-06-22 | The United States Of America As Represented By The Secretary Of The Army | Protein biomarker for mustard chemical injury |
| EA200000087A1 (ru) | 1997-07-01 | 2000-08-28 | Атеродженикс, Инк. | Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта |
| EP1051490A2 (en) * | 1998-01-30 | 2000-11-15 | Cold Spring Harbor Laboratory | Modulation of cell proliferation, methods and reagents |
| GB9805868D0 (en) | 1998-03-20 | 1998-05-13 | Zeneca Ltd | Anti-tumour agents |
| US6399678B2 (en) * | 1998-06-25 | 2002-06-04 | Tamko Roofing Products | Silicone-aggregate mixtures for pumping and spraying applications |
| US20060079492A1 (en) * | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
| US6329148B1 (en) | 1999-02-16 | 2001-12-11 | The Board Of Trustees Of The Leland Stanford University | Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells |
| US6017902A (en) | 1999-02-25 | 2000-01-25 | Brookhaven Science Associates | Boron containing amino acid compounds and methods for their use |
| US20020146692A1 (en) | 2000-01-21 | 2002-10-10 | Victoria Yamazaki | Methods and materials relating to G protein-coupled receptor-like polypeptides and polynucleotides |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20030215471A1 (en) * | 2001-01-31 | 2003-11-20 | Wilmott James M. | Surfactant free topical compositions and method for rapid preparation thereof |
| US7547673B2 (en) | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| WO2003094954A1 (en) | 2001-09-25 | 2003-11-20 | Quick Med Technologies, Inc. | Composition and method for minimizing or avoiding adverse effects of vesicants |
| US20030082229A1 (en) | 2001-11-01 | 2003-05-01 | Board Of Regents, The University Of Texas Systems | Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use |
| WO2004043466A1 (en) * | 2002-11-12 | 2004-05-27 | Jewish General Hospital | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia |
| EP1569616A2 (en) | 2002-12-04 | 2005-09-07 | Technologies Biolactis Inc. | An exopolysaccharides delivery system for active molecules |
| US20050039228A1 (en) | 2003-06-19 | 2005-02-17 | The Samuel Roberts Noble Foundation | Methods and compositions for analysis of plant gene function |
| WO2005007129A2 (en) | 2003-07-17 | 2005-01-27 | Angiotech International Ag | Topical formulations with bioactive components |
| US20070287719A1 (en) | 2005-03-11 | 2007-12-13 | Pfizer Inc | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| US20110039943A1 (en) | 2005-03-14 | 2011-02-17 | Robert Alonso | Methods for treating skin disorders with topical nitrogen mustard compositions |
| US20060281720A1 (en) | 2005-06-08 | 2006-12-14 | Loria Roger M | 5-Androstenediol As An Inhibitor of Gliomas |
| LT3494960T (lt) | 2008-03-27 | 2021-02-25 | Helsinn Healthcare Sa | Stabilizuotos alkilinimo agentų kompozicijos ir jų naudojimo būdai |
-
2009
- 2009-03-11 LT LTEP18214529.2T patent/LT3494960T/lt unknown
- 2009-03-11 TR TR2019/07794T patent/TR201907794T4/tr unknown
- 2009-03-11 SI SI200931973T patent/SI2273876T1/sl unknown
- 2009-03-11 CN CN201710563914.2A patent/CN107149591A/zh active Pending
- 2009-03-11 ES ES09724939T patent/ES2727523T3/es active Active
- 2009-03-11 PT PT09724939T patent/PT2273876T/pt unknown
- 2009-03-11 PT PT182145292T patent/PT3494960T/pt unknown
- 2009-03-11 LT LTEP09724939.5T patent/LT2273876T/lt unknown
- 2009-03-11 HU HUE09724939A patent/HUE043767T2/hu unknown
- 2009-03-11 EP EP18214529.2A patent/EP3494960B1/en active Active
- 2009-03-11 WO PCT/US2009/036737 patent/WO2009120493A2/en active Application Filing
- 2009-03-11 CN CN2009801186378A patent/CN102036557A/zh active Pending
- 2009-03-11 HU HUE18214529A patent/HUE053482T2/hu unknown
- 2009-03-11 EP EP09724939.5A patent/EP2273876B1/en active Active
- 2009-03-11 ES ES18214529T patent/ES2848841T3/es active Active
- 2009-03-11 PL PL09724939T patent/PL2273876T3/pl unknown
- 2009-03-11 PL PL18214529T patent/PL3494960T3/pl unknown
- 2009-03-11 SI SI200932113T patent/SI3494960T1/sl unknown
- 2009-03-11 DK DK18214529.2T patent/DK3494960T3/da active
- 2009-03-11 US US12/401,812 patent/US8501817B2/en active Active
-
2013
- 2013-06-06 US US13/911,217 patent/US20140142193A1/en not_active Abandoned
-
2019
- 2019-03-21 HR HRP20190551TT patent/HRP20190551T1/hr unknown
- 2019-05-24 CY CY20191100556T patent/CY1121777T1/el unknown
-
2021
- 2021-02-08 CY CY20211100102T patent/CY1123974T1/el unknown
- 2021-02-18 HR HRP20210283TT patent/HRP20210283T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140142193A1 (en) | 2014-05-22 |
| EP2273876A2 (en) | 2011-01-19 |
| US20100029783A9 (en) | 2010-02-04 |
| HRP20190551T1 (hr) | 2019-05-03 |
| SI2273876T1 (sl) | 2019-09-30 |
| CY1123974T1 (el) | 2022-05-27 |
| ES2727523T3 (es) | 2019-10-16 |
| EP3494960B1 (en) | 2020-11-25 |
| TR201907794T4 (tr) | 2019-06-21 |
| CY1121777T1 (el) | 2020-07-31 |
| US20090247645A1 (en) | 2009-10-01 |
| EP2273876B1 (en) | 2019-03-06 |
| EP3494960A1 (en) | 2019-06-12 |
| EP2273876A4 (en) | 2013-10-23 |
| LT2273876T (lt) | 2019-05-27 |
| PT3494960T (pt) | 2021-02-09 |
| ES2848841T3 (es) | 2021-08-12 |
| HUE053482T2 (hu) | 2021-06-28 |
| DK3494960T3 (da) | 2021-01-25 |
| CN102036557A (zh) | 2011-04-27 |
| CN107149591A (zh) | 2017-09-12 |
| WO2009120493A2 (en) | 2009-10-01 |
| PL3494960T3 (pl) | 2021-05-17 |
| US8501817B2 (en) | 2013-08-06 |
| PL2273876T3 (pl) | 2019-09-30 |
| HUE043767T2 (hu) | 2019-09-30 |
| PT2273876T (pt) | 2019-06-04 |
| WO2009120493A3 (en) | 2010-03-04 |
| LT3494960T (lt) | 2021-02-25 |
| SI3494960T1 (sl) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210283T1 (hr) | Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
| CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| NZ599001A (en) | compositions comprising bis(2-chloroethyl)methylamine (mechlorethamine) | |
| NZ702571A (en) | 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors | |
| ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| DOP2012000225A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| UY31272A1 (es) | Nuevos derivados de ácido azabifenilaminobenzoico | |
| GT201300266A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| UY31294A1 (es) | Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos | |
| BR112014014341A2 (pt) | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| PH12015500063B1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| MX2011008910A (es) | Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson. | |
| ECSP11011073A (es) | Nuevas lactamas como inhibidores de beta secretasa | |
| BR112014016661A8 (pt) | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma | |
| UY31672A1 (es) | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| BR112013033568A2 (pt) | compostos éter amidopiridil e composições e seu uso contra parasitas | |
| PE20160846A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c | |
| BR112014001083B8 (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto | |
| UY31839A (es) | Compuestos |